1
|
Allard M, Pflaum R, Poisson A, Bonnet F. Protocole d’étude : étude de la relation entre les concentrations résiduelles de testostérone et la fonction des cellules de Sertoli chez les femmes transgenres. Annales d'Endocrinologie 2023. [DOI: 10.1016/j.ando.2022.12.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
|
2
|
Poisson A, Thobois S. Allucinazioni e morbo di Parkinson. Neurologia 2022. [DOI: 10.1016/s1634-7072(21)45999-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
3
|
Farfour E, Degand N, Riverain E, Fihman V, Le Brun C, Péan de Ponfilly G, Muggeo A, Jousset A, Piau C, Lesprit P, Chatelain N, Dortet L, Poisson A, Guillard T, Limelette A, Mizrahi A, Le Monnier A, Fournier D, Potron A, Morand P, Janvier F, Otto MP, Woerther PL, Decousser JW, Corvec S, Plouzeau-Jayle C, Broutin L, Yin N, Héry-Arnaud G, Beauruelle C, Grillon A, Lecuru M, Bille E, Godreuil S, Jean Pierre H, Amara M, Henry A, Zahar JR, Carbonelle E, Jaureguy F, Lomont A, Isnard C, Cattoir V, Canis F, Diedrich T, Flevin E, Merens A, Jacquier H, Gyde E. Fosfomycin, from susceptibility to resistance: Impact of the new guidelines on breakpoints. Med Mal Infect 2020; 50:611-616. [DOI: 10.1016/j.medmal.2020.07.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Accepted: 07/08/2020] [Indexed: 12/17/2022]
|
4
|
Poisson A, Favre E, Peyroux E, Nicolas A, Schlutz Bolard C, Demily C. An ambiguous psychiatric diagnosis resolved by genetic investigations. Schizophr Res 2018; 195:577-578. [PMID: 28943095 DOI: 10.1016/j.schres.2017.09.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 09/18/2017] [Accepted: 09/19/2017] [Indexed: 11/29/2022]
Affiliation(s)
- A Poisson
- GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Team (CNRS & Lyon 1 Claude Bernard University), Lyon, France; Université de Lyon, Université Lyon 1, Faculté de médecine et de maïeutique Lyon Sud Charles Mérieux, Lyon, France.
| | - E Favre
- GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Team (CNRS & Lyon 1 Claude Bernard University), Lyon, France
| | - E Peyroux
- GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Team (CNRS & Lyon 1 Claude Bernard University), Lyon, France
| | - A Nicolas
- GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Team (CNRS & Lyon 1 Claude Bernard University), Lyon, France; Université de Lyon, Université Lyon 1, Faculté de médecine et de maïeutique Lyon Sud Charles Mérieux, Lyon, France
| | - C Schlutz Bolard
- HCL, Department of Genetics, Reference Center for Developmental Anomalies and Malformation Syndromes, Bron, France; GENDEV, Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR529, UCBL1, Lyon, France
| | - C Demily
- GénoPsy, Reference Center for Diagnosis and Management of Genetic Psychiatric Disorders, Centre Hospitalier le Vinatier and EDR-Psy Team (CNRS & Lyon 1 Claude Bernard University), Lyon, France; Université de Lyon, Université Lyon 1, Faculté de médecine et de maïeutique Lyon Sud Charles Mérieux, Lyon, France
| |
Collapse
|
5
|
Poisson A, Schluth Bolard C, Martin B, Babinet MN, Sanlaville D, Demily C. 16q12.2q21: A new susceptibility locus for schizophrenia? Schizophr Res 2016; 178:109-111. [PMID: 27617415 DOI: 10.1016/j.schres.2016.09.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 09/02/2016] [Accepted: 09/03/2016] [Indexed: 11/17/2022]
Affiliation(s)
- A Poisson
- GénoPsy, Center for Diagnosis and management of genetic psychiatric disorders, Centre Hospitalier le Vinatier and EDR-Psy team (CNRS & Lyon 1 Claude Bernard University), Lyon, France.
| | - C Schluth Bolard
- HCL, Department of Genetics, Reference Center for Developmental Anomalies and Malformation Syndromes, Bron, France; GENDEV, Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR529, UCBL1, Lyon, France
| | - B Martin
- SUR/CL3R, UMR 5229 (CNRS & Lyon 1 University) CH le Vinatier, Bron, France
| | - M N Babinet
- GénoPsy, Center for Diagnosis and management of genetic psychiatric disorders, Centre Hospitalier le Vinatier and EDR-Psy team (CNRS & Lyon 1 Claude Bernard University), Lyon, France
| | - D Sanlaville
- HCL, Department of Genetics, Reference Center for Developmental Anomalies and Malformation Syndromes, Bron, France; GENDEV, Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS UMR529, UCBL1, Lyon, France
| | - C Demily
- GénoPsy, Center for Diagnosis and management of genetic psychiatric disorders, Centre Hospitalier le Vinatier and EDR-Psy team (CNRS & Lyon 1 Claude Bernard University), Lyon, France
| |
Collapse
|
6
|
Poisson A, Nicolas A, Sanlaville D, Cochat P, De Leersnyder H, Rigard C, Franco P, des Portes V, Edery P, Demily C. [Smith-Magenis syndrome is an association of behavioral and sleep/wake circadian rhythm disorders]. Arch Pediatr 2015; 22:638-45. [PMID: 25934608 DOI: 10.1016/j.arcped.2015.03.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2014] [Revised: 12/21/2014] [Accepted: 03/21/2015] [Indexed: 12/12/2022]
Abstract
Smith-Magenis syndrome (SMS) is a genetic disorder characterized by the association of facial dysmorphism, oral speech delay, as well as behavioral and sleep/wake circadian rhythm disorders. Most SMS cases (90%) are due to a 17p11.2 deletion encompassing the RAI1 gene; other cases stem from mutations of the RAI1 gene. Behavioral issues may include frequent outbursts, attention deficit/hyperactivity disorders, self-injuries with onychotillomania and polyembolokoilamania (insertion of objects into bodily orifices), etc. It is noteworthy that the longer the speech delay and the more severe the sleep disorders, the more severe the behavioral issues are. Typical sleep/wake circadian rhythm disorders associate excessive daytime sleepiness with nocturnal agitation. They are related to an inversion of the physiological melatonin secretion cycle. Yet, with an adapted therapeutic strategy, circadian rhythm disorders can radically improve. Usually an association of beta-blockers in the morning (stops daily melatonin secretion) and melatonin in the evening (mimics the evening deficient peak) is used. Once the sleep disorders are controlled, effective treatment of the remaining psychiatric features is needed. Unfortunately, as for many orphan diseases, objective guidelines have not been drawn up. However, efforts should be focused on improving communication skills. In the same vein, attention deficit/hyperactivity disorders, aggressiveness, and anxiety should be identified and specifically treated. This whole appropriate medical management is underpinned by the diagnosis of SMS. Diagnostic strategies include fluorescent in situ hybridization (FISH) or array comparative genomic hybridization (array CGH) when a microdeletion is sought and Sanger sequencing when a point mutation is suspected. Thus, the diagnosis of SMS can be made from a simple blood sample and should be questioned in subjects of any age presenting with an association of facial dysmorphism, speech delay with behavioral and sleep/wake circadian rhythm disorders, and other anomalies including short stature and mild dysmorphic features.
Collapse
Affiliation(s)
- A Poisson
- UDEIP, centre de dépistage et de prise en charge des troubles psychiatriques d'origine génétique, centre hospitalier le Vinatier, 95, boulevard Pinel, 69678 Bron cedex, France; Centre de neurosciences cognitives, UMR 5229 CNRS, 69500 Bron, France; Université Lyon 1, 69500 Lyon, France.
| | - A Nicolas
- UDEIP, centre de dépistage et de prise en charge des troubles psychiatriques d'origine génétique, centre hospitalier le Vinatier, 95, boulevard Pinel, 69678 Bron cedex, France; Université Lyon 1, 69500 Lyon, France
| | - D Sanlaville
- Université Lyon 1, 69500 Lyon, France; Service de génétique, centre des anomalies du développement, laboratoire de cytogénétique, hospices civils de Lyon, 69500 Bron, France
| | - P Cochat
- Université Lyon 1, 69500 Lyon, France; Service de néphrologie et rhumatologie pédiatrique, centre de référence des maladies rénales rares, Inserm U820, hospices civils de Lyon, 69500 Bron, France
| | - H De Leersnyder
- Centre de recherche en neurosciences de Lyon, Inserm U1028, CNRS UMR 5292, UCBL, équipe TIGER, 69500 Bron, France
| | - C Rigard
- UDEIP, centre de dépistage et de prise en charge des troubles psychiatriques d'origine génétique, centre hospitalier le Vinatier, 95, boulevard Pinel, 69678 Bron cedex, France; Centre de neurosciences cognitives, UMR 5229 CNRS, 69500 Bron, France
| | - P Franco
- Université Lyon 1, 69500 Lyon, France; Unité d'hypnologie, service de neuropédiatrie, Inserm U 628, hospices civils de Lyon, 69500 Bron, France
| | - V des Portes
- Université Lyon 1, 69500 Lyon, France; Centre de référence X fragile et autres déficiences intellectuelles de causes rares, hospices civils de Lyon, 69500 Bron, France
| | - P Edery
- Service de génétique, centre de référence des anomalies du développement et des syndromes malformatifs, hospices civils de Lyon, 69500 Bron, France; Université Lyon 1, 69500 Lyon, France; Centre de référence X fragile et autres déficiences intellectuelles de causes rares, hospices civils de Lyon, 69500 Bron, France
| | - C Demily
- UDEIP, centre de dépistage et de prise en charge des troubles psychiatriques d'origine génétique, centre hospitalier le Vinatier, 95, boulevard Pinel, 69678 Bron cedex, France; Centre de neurosciences cognitives, UMR 5229 CNRS, 69500 Bron, France; Université Lyon 1, 69500 Lyon, France
| |
Collapse
|
7
|
Abstract
Les hallucinations dans la maladie de Parkinson sont une complication relativement fréquente au stade des complications cognitives de la maladie. Étant généralement peu inquiétantes, le sujet ne les rapportera pas toujours spontanément. Pourtant, elles peuvent en effet signer l’entrée dans une psychose ou une démence parkinsonienne. Elles grèvent la qualité de vie du patient, de son entourage et parfois mettent en péril le maintien à domicile des sujets. Elles ne doivent donc pas êtres négligées. Classiquement les hallucinations dans la maladie de Parkinson sont d’abord visuelles, parfois mineures (simples de passage à la périphérie du champ visuel) ou au contraire très élaborées.Leur physiopathologie demeure imparfaitement connue. L’atteinte visuelle centrale, et notamment au niveau de l’intégration des données visuelles semble jour un rôle majeur. Cependant, d’autres systèmes dont le fonctionnement est perturbé dans la maladie de Parkinson sont impliqués dans la survenue des hallucinations : système visuel périphérique (rétine), voies régulatrices du cycle veille sommeil et notamment du sommeil paradoxal et enfin le système frontal et notamment exécutif.La prise en charge des hallucinations dans la maladie de Parkinson est relativement stéréotypée. Il faut tout d’abord dépister pour les éliminer les facteurs favorisants, notamment de type médicamenteux ou métabolique. Si les hallucinations persistent, le traitement antiparkinsonien doit être revu rapidement avec en priorité la diminution ou l’arrêt des anticholinergiques, des agonistes dopaminergiques et de l’amantadine, puis des inhibiteurs de la catéchol-O-méthyltransférase (COMT) et de la monoaminoxydase B (MAO B). Au besoin, les doses de dopamine peuvent être diminuées. Ces adaptations thérapeutiques permettent en général de contrôler les hallucinations, parfois au détriment de l’état moteur. Malgré tout, si les hallucinations persistent, un traitement neuroleptique par petites doses de clozapine peut être indiqué avec en générale une excellente efficacité.
Collapse
|
8
|
Poisson A, Thobois S. Allucinazioni e malattia di Parkinson. Neurologia 2014. [DOI: 10.1016/s1634-7072(14)67224-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Laurencin C, Broussolle E, Streichenberger N, Thobois S, Quadrio I, Poisson A. Parkinson's with tardive Creutzfeldt-Jakob disease: when there is more to it than meets the eye. Rev Neurol (Paris) 2014; 170:148-50. [PMID: 24507634 DOI: 10.1016/j.neurol.2013.08.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2012] [Revised: 08/02/2013] [Accepted: 08/27/2013] [Indexed: 10/25/2022]
Affiliation(s)
- C Laurencin
- Service de neurologie C, université Lyon 1, hospices civils de Lyon, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, 69677 Bron, France.
| | - E Broussolle
- Service de neurologie C, université Lyon 1, hospices civils de Lyon, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, 69677 Bron, France; CNRS, UMR 5229, centre de neuroscience cognitive, 67, boulevard Pinel, 69500 Bron, France
| | - N Streichenberger
- Inserm U 1028, CNRS, UMR 5292, service d'anatomopathologie, université Lyon 1, hospices civils de Lyon, groupement hospitalier Est, 59, boulevard Pinel, 69677 Bron, France
| | - S Thobois
- Service de neurologie C, université Lyon 1, hospices civils de Lyon, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, 69677 Bron, France; CNRS, UMR 5229, centre de neuroscience cognitive, 67, boulevard Pinel, 69500 Bron, France
| | - I Quadrio
- Inserm U 1028, CNRS UMR 5292, service de neurobiologie, centre de biologie et pathologie Est, hospices civils de Lyon, groupement hospitalier Est, 59, boulevard Pinel, 69677 Bron, France
| | - A Poisson
- Service de neurologie C, université Lyon 1, hospices civils de Lyon, hôpital neurologique Pierre-Wertheimer, 59, boulevard Pinel, 69677 Bron, France; CNRS, UMR 5229, centre de neuroscience cognitive, 67, boulevard Pinel, 69500 Bron, France
| |
Collapse
|
10
|
Demily C, Saucourt G, Rigard C, Poisson A, Franck N, Edery P, d’Amato T. Création d’un centre de dépistage et de prise en charge des troubles psychiatriques d’origine génétique à Lyon. Eur Psychiatry 2013. [DOI: 10.1016/j.eurpsy.2013.09.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
La prise en charge des troubles mentaux résultant d’une affection génétique reste complexe actuellement. D’une part, l’offre de soins psychiatriques spécifique destinée à ces populations particulières est quasiment inexistante et, d’autre part, le diagnostic d’une affection somatique qui est à l’origine des symptômes psychiatriques n’est pas souvent posé si les points d’appel cliniques somatiques ne sont pas au premier plan. La question de l’organicité des troubles mentaux est pourtant majeure puisque 6 % des psychoses seraient secondaires à une affection organique. Il s’agit essentiellement de psychoses observées dans un cadre syndromique. Notons ici qu’il est également fort probable que certaines psychoses isolées (non syndromiques) aient une composante constitutionnelle, c’est-à-dire que leur survenue pourrait être favorisée par une constitution génétique particulière. La méconnaissance d’une pathologie sous-jacente à des troubles d’allure psychiatrique peut induire une véritable « perte de chance » pour le patient. Parmi les affections somatiques responsables des troubles psychiatriques, les affections cytogénétiques (par exemple, la microdélétion 22q11, le syndrome de Prader-Willi ou le syndrome de Smith-Magenis…) occupent une place importante et restent parfois méconnues et difficiles à repérer. Les maladies héréditaires du métabolisme (comme la maladie de Wilson ou les troubles du cycle de l’urée…) sont également pourvoyeuses de troubles mentaux. Le point important est que certaines de ces affections sont accessibles à un traitement étiologique, d’autres pouvant bénéficier de soins de stimulation adaptés au déficit. Fort de ce constat, il nous est apparu important de pouvoir développer un outil en direction de ces patients afin d’organiser le dépistage, des soins spécifiques et des stratégies de réinsertion socio-professionnelle. Parallèlement, nous avons constaté que les patients déjà pris en charge pour une affection génétique en Centre expert ne bénéficiaient pas toujours de soins psychiatriques adaptés, faute de connaissance précise de leurs difficultés. Le « Centre régional de dépistage et de prise en charge des troubles psychiatriques d’origine génétique » s’est structuré à Lyon en décembre 2012 grâce au soutien de l’ARS Rhône-Alpes et à une collaboration étroite entre les services de psychiatrie et de génétique clinique. Ce centre accueille et évalue les patients selon un protocole particulier qui sera détaillé.
Collapse
|
11
|
Escarguel B, Thomas G, Tchouhadjian C, Chollat Namy A, Foa C, Paoli JB, Poisson A. Biopsies médiastinales à la pince en échoendobronchique : une nouvelle approche en pratique quotidienne. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Thobois S, Ballanger B, Poisson A, Broussolle E. [Imaging non motor signs in Parkinson's disease]. Rev Neurol (Paris) 2012; 168:576-84. [PMID: 22921250 DOI: 10.1016/j.neurol.2012.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Revised: 05/25/2012] [Accepted: 05/29/2012] [Indexed: 11/18/2022]
Abstract
Parkinson's disease is mainly considered as a motor disorder defined by a motor triad. However, various non-motor manifestations may be encountered in Parkinson's disease, including hyposmia, pain, fatigue, sleep disorders, cognitive and behavioral disorders. The pathophysiology of these signs is complex, not univocal and remains poorly understood. Functional imaging techniques either by positron emission tomography, single photon emission tomography or functional magnetic resonance imaging provide an invaluable opportunity to better understand the pathophysiology of these signs. In this paper, we present a review of the recent advances provided by functional imaging in this area.
Collapse
Affiliation(s)
- S Thobois
- CNRS, UMR 5229, centre de neurosciences cognitives, Bron cedex, France.
| | | | | | | |
Collapse
|
13
|
Poisson A, Krack P, Thobois S, Loiraud C, Serra G, Vial C, Broussolle E. History of the ‘geste antagoniste’ sign in cervical dystonia. J Neurol 2012; 259:1580-4. [DOI: 10.1007/s00415-011-6380-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2011] [Revised: 12/07/2011] [Accepted: 12/13/2011] [Indexed: 12/01/2022]
|
14
|
Labouba I, Poisson A, Delvoye N, Mes-Masson A, Saad F. Effect of NF-kappaB RelB subunit expression on the biology of prostate cancer cells. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Péant B, Huon Y, Poisson A, Leclerc-Desaulniers K, Delvoye N, Mes-Masson A, Saad F. Antagonist effect of the androgen-receptor activity and IKKe expression in prostate cancer xenograft growth. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Adamec D, Xie J, Poisson A, Broussolle E, Thobois S. Xeroderma pigmentosum: a rare cause of chorea. Rev Neurol (Paris) 2011; 167:837-40. [PMID: 21514943 DOI: 10.1016/j.neurol.2011.02.039] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2011] [Revised: 02/09/2011] [Accepted: 02/23/2011] [Indexed: 11/27/2022]
Abstract
Xeroderma pigmentosum (XP) is an uncommon inherited dermatological disorder characterized by a high degree of skin photosensitivity with development of carcinomas at an early age. Neurological manifestations may be encountered in XP but few detailed descriptions have been provided. Here we describe a sister and a brother presenting chorea, dystonia, myoclonus, ataxia and polyneuropathy related to XP.
Collapse
Affiliation(s)
- D Adamec
- Service de Neurologie C, Hôpital Neurologique et Neurochirurgical Pierre-Wertheimer, Hospices Civils de Lyon, Université Lyon-I, 59, Boulevard Pinel, 69677 Bron, France
| | | | | | | | | |
Collapse
|
17
|
Thobois S, Ardouin C, Schmitt E, Lhommée E, Klinger H, Xie J, Lagrange C, Kistner A, Aya Kombo M, Fleury V, Poisson A, Fraix V, Broussolle E, Pollak P, Krack P. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment]. Rev Neurol (Paris) 2010; 166:816-21. [PMID: 20739041 DOI: 10.1016/j.neurol.2010.07.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2010] [Accepted: 07/07/2010] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Behavioral changes in Parkinson's disease are complex and their pathophysiology is not yet fully understood. The dopaminergic system seems to play a major role and most of the behavioral disorders in Parkinson's disease can be classified into either hypodopaminergic if related to the disease itself or hyperdopaminergic if related to dopaminergic treatment. STATE OF THE ART Subthalamic stimulation, which enables withdrawal of dopaminergic medication at an advanced stage in the disease, provides a model for the study of certain nonmotor, dopamine-sensitive symptoms. Such a study has shown that apathy, which is the most frequent behavioral problem in Parkinson's disease, is part of a much broader hypodopaminergic behavioral syndrome which also includes anxiety and depression. Nonmotor fluctuations--essential fluctuations in the patient's psychological state--are an expression of mesolimbic denervation, as shown in positron emission tomography. Drug-induced sensitization of the denervated mesolimbic system accounts for hyperdopaminergic behavioral problems that encompass impulse control disorders that can be alternatively classified as behavioral addictions. The association of impulse control disorders and addiction to the dopaminergic medication has been called dopamine dysregulation syndrome. While L-dopa is the most effective treatment for motor symptoms, dopamine agonists are more effective in improving the nonmotor levodopa-sensitive symptoms. On the other hand, L-dopa induces more motor complications and dopamine agonist more behavioral side effects. There is increasing data and awareness that patients' quality of life appears to be dictated by hypo- and hyperdopaminergic psychological symptoms stemming from mesolimbic denervation and dopaminergic treatment rather than by motor symptoms and motor complications related to nigrostriatal denervation and dopaminergic treatment. PERSPECTIVES Better management requires knowledge of the clinical syndromes of hyper- and hypodopaminergic behaviors and nonmotor fluctuations, a better understanding of their underlying mechanisms and the development of new evaluation tools for these nonmotor symptoms. CONCLUSIONS The neurologist who strives to gain mastery of dopaminergic treatment needs to fine tune the dosage of levodopa and dopamine agonists on an individual basis, depending on the presence of motor and nonmotor signs respectively.
Collapse
Affiliation(s)
- S Thobois
- Service de Neurologie C, Université Lyon-I, Hospices Civils, Hôpital Neurologique Pierre-Wertheimer, 69500 Bron, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
|
19
|
Bizon G, Biju-Duval B, Letouzey J, Monod O, Poisson A, Ozer B, Oztumer E. Nouvelles précisions stratigraphiques concernat les bassins tertiaires du sud de la Turquie (Antalya, Mut, Adana). ACTA ACUST UNITED AC 2006. [DOI: 10.2516/ogst:1974014] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
20
|
Pradal M, Retornaz K, Poisson A. [Chronic cough in childhood]. Rev Mal Respir 2005; 21:743-62. [PMID: 15536376 PMCID: PMC7135783 DOI: 10.1016/s0761-8425(04)71416-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Introduction La toux chronique de l’enfant bien que moins fréquente que les toux répétées liées aux infections virales reste un problème diagnostique parfois difficile à résoudre. États des connaissances La majorité des auteurs estiment que sa durée doit être supérieure à trois semaines. Peu d’études ont été consacrées au diagnostic étiologique de la toux chronique chez l’enfant mais celles-ci retrouvent les mêmes causes principales que chez l’adulte : l’asthme, les pathologies ORL (dont la sinusite), le reflux gastro-œsophagien. Chaque tranche d’âge connaît des étiologies plus spécifiques ; notamment malformatives entre 0 et 1 an, et toux psychogène chez l’adolescent. Perspectives Des techniques « nouvelles » comme l’étude de l’expectoration induite permettent d’affiner le diagnostic d’une toux chronique de l’enfant en tout cas après 7 ans. La découverte d’une bronchite à éosinophiles quelle soit associée ou pas à une hyperréactivité bronchique a des conséquences thérapeutiques indiscutables compte tenu de sa corticosensibilité. Conclusions L’exploration d’une toux chronique de l’enfant doit reposer sur un raisonnement anatomique et sur des arguments de fréquence. Le contrôle et la disparition de la toux ne seront possibles qu’avec un diagnostic précis et un traitement adapté.
Collapse
Affiliation(s)
- M Pradal
- Service de Pneumologie, Hôpital Paul Desbief, Marseille, France.
| | | | | |
Collapse
|
21
|
Poisson A, Thomas G, Jean-Landais N, Giaufre E. [Rapid acquired tolerance to cow's milk by oral route in a case of severe childhood food allergy]. Allerg Immunol (Paris) 1988; 20:67-8. [PMID: 3134907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
An attempt to desensitize to cow's milk a 5 year-old girl who had been forced to follow a strict egg and milk-free diet with concomitant impossibility of attendance at school, posed major practical problems. In a hospital environment, under cover of treatment with Nalcron and Solemedrol, the re-introduction of milk was started with 10(-10) ml of milk. After a severe episode on the 1st day, the child was able to take 100 ml on the 10th day and thereafter. Today, the child continues with Nalcron treatment, but she no longer has a diet and she leads a normal lifestyle.
Collapse
Affiliation(s)
- A Poisson
- Service de pneumologie, Hôpital St-Joseph
| | | | | | | |
Collapse
|
22
|
|
23
|
|
24
|
Vollmer KO, Liedtke B, Poisson A, von Hodenberg A, Steinbrecher W. Metabolism of thymoxamine. I. Studies with 14C-thymoxamine in rats. Eur J Drug Metab Pharmacokinet 1985; 10:61-9. [PMID: 3161738 DOI: 10.1007/bf03189698] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Thymoxamine is rapidly and completely absorbed in rats. It is a prodrug which does not enter the systemic circulation in its unchanged form. After either oral or intravenous administration it undergoes rapid and intense metabolism involving four biotransformation reactions: Enzymatic hydrolysis to the corresponding phenol (metabolite I), Monodemethylation to metabolite II, Sulfate conjugation of I and II (metabolites III and IV) and Conjugation of I and II with glucuronic acid (metabolites V and VI). With these 6 metabolites identified approximately 95% of the radioactivity can be accounted for in plasma, urine and bile. Whereas the systemic availability of I and II is low, III and IV show high bioavailability. Metabolites I to IV are pharmacologically active, while III and IV are less potent than I and II. The radioactivity distribution in tissues is different after oral and intravenous administration consistent with the higher portion of unconjugated metabolites in the body after administration by parenteral route. Although 60% of the labelled compounds is eliminated via bile, the radioactive compounds are almost completely excreted in the urine after both routes of administration. This demonstrates complete reabsorption of the biliary metabolites. Secondary peaks of radioactivity in plasma and organs at 4 hours are explained by the participation of the metabolites in the enterohepatic circulation.
Collapse
|
25
|
Abstract
Thymoxamine is rapidly and completely absorbed in man. Rapid biotransformation is observed after intravenous and oral administration of 40 mg 14C-thymoxamine HCl. No unchanged compound is found in the body. More than 90% of plasma and urine radioactivity could be ascribed to six metabolites: the desacetyl compound (metabolite I), the monodemethylated metabolite I (metabolite II), the sulfate conjugates of I and II (metabolites III and IV) and the glucuronides of I and II (metabolites V and VI). The unconjugated metabolites are observed in plasma only after intravenous administration. Similar patterns for polar metabolites are found in plasma and urine for both routes of administration. The sulfate fraction amounts to about 50-60% and the glucuronide fraction to about 30-40% of the radioactivity, the conjugates of metabolite I being more abundant than those of metabolite II. The elimination of the metabolites is rapid, the half-life of radioactivity elimination being 1.5 h during the first 12 hours and 12 h thereafter. 80% of the radioactivity dose is recovered in the urine within 4 hours. Recovery after four days amounts to 99.8% (i.v.) and 97.7% (oral). The results are discussed with regard to the application of the drug in man, taking into account that not only the unconjugated metabolites but also the sulfate conjugates are pharmacologically active.
Collapse
|
26
|
Poisson A, Lebel J, Brunet C. Influence of local variations in the ionic ratios on the density of seawater in the St. Lawrence area. ACTA ACUST UNITED AC 1980. [DOI: 10.1016/0198-0149(80)90043-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Ricou LE, Marcoux J, Poisson A. L'allochtonie des Bey Daglari orientaux; reconstruction palinspastique des Taurides occidentales. ACTA ACUST UNITED AC 1979. [DOI: 10.2113/gssgfbull.s7-xxi.2.125] [Citation(s) in RCA: 39] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
28
|
Dugué P, Poisson A, Vervloet D, Serano E, Charpin J. [Hematosis during bronchial fiberscopy]. Nouv Presse Med 1977; 6:852. [PMID: 15236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
29
|
Brunn JH, Argyriadis I, Ricou LE, Poisson A, Marcoux J, de Graciansky PC. Elements majeurs de liaison entre Taurides et Hellenides. ACTA ACUST UNITED AC 1976. [DOI: 10.2113/gssgfbull.s7-xviii.2.481] [Citation(s) in RCA: 36] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
30
|
Vollmer KO, Poisson A. [Human pharmacokinetics of the new potent analgesic DL-trans-2-di-methylamino-1-phenyl-cyclohex-3-en-trans-1-carboxylic acid ethyl ester hydrochloride. 1. Blood level and excretion with urine and feces after single oral administration of 14C-labeled substance]. Arzneimittelforschung 1970; 20:992-5. [PMID: 5536521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|